Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Lung Neoplasms 21Multiple Myeloma 20Neoplasm Metastasis 18Lymphoma 16Leukemia, Myeloid, Acute 15Breast Neoplasms 14Prostatic Neoplasms 12Colorectal Neoplasms 12Carcinoma, Non-Small-Cell Lung 12Ovarian Neoplasms 11Melanoma 10Glioma 10Fallopian Tube Neoplasms 10Urinary Bladder Neoplasms 9Pancreatic Neoplasms 9Triple Negative Breast Neoplasms 8Sarcoma 8Carcinoma, Renal Cell 8Medulloblastoma 7Cholangiocarcinoma 7Burkitt Lymphoma 7Small Cell Lung Carcinoma 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Oropharyngeal Neoplasms 6Leukemia, Lymphocytic, Chronic, B-Cell 6Leukemia, Biphenotypic, Acute 6Glioblastoma 6Endometrial Neoplasms 6Carcinosarcoma 6Uterine Cervical Neoplasms 5

Interventions

ipatasertib 1Telemedicine 1Specimen Handling 1Sentinel Lymph Node Biopsy 1Ovariectomy 1Megestrol Acetate 1Magnetic Resonance Spectroscopy 1Interviews as Topic 1Hysterectomy 1Health Promotion 1Exercise Test 1Educational Status 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma × Specimen Handling × Clear all
NCT05538897 2026-05-13

Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
96 enrolled
Gynecologic

FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡